Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 367

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Diagnostic value and cost‐effectiveness of on‐site evaluation of fine‐needle aspiration specimens: Review of 5,688 cases

Nasuti, Joseph F., Gupta, Prabodh K., Baloch, Zubair W.·2002·Diagnostic Cytopathology

Abstract

Fine‐needle aspiration (FNA) has proven to be a safe, economical, accurate, and rapid diagnostic technique. A successful FNA requires a specimen with adequate cellularity, high‐quality preparation, an experienced aspirator, and cytopathologist. Up to 32% of FNAs in various organs (thyroid, breast, lung, etc.) may be nondiagnostic due to scant cellularity and poor preparation. On‐site immediate evaluation of FNA specimens can be beneficial in determination of adequacy: triage for ancillary studies and provide a preliminary diagnosis of the specimen, which often facilitates rapid clinical decisions. In this study, we compared the on‐site FNA interpretation with the final diagnosis and calculated its cost benefit. Reports of 5,688 on‐site FNA cases from the files of the University of Pennsylvania Medical Center over a 5‐yr period (1/1/96–12/31/00) were reviewed. Data of the immediate on‐site interpretation and the final diagnosis in each case were compared to determine the diagnostic accuracy, clinical utility, and cost‐effectiveness of on‐site FNA evaluation. At our institution the average cost per FNA based on laboratory technical and professional fees ($1,743) and the weighted average cost, based on utilization, of ancillary laboratory studies ($328) and guidance procedures ($1,025) is $3,096. An additional fee of $231 per case is charged for on‐site FNA evaluation by an attending cytopathologist. The average reported rate of nondiagnostic FNAs without on‐site evaluation is 20%. Our own nondiagnostic rate for FNAs with on‐site evaluation is 0.98%. If one assumes that patients will undergo a repeat FNA for each nondiagnostic specimen, the estimated additional cost in direct institutional charges is $2,022,626 over 5 yr or $404,525 per yr without on‐site evaluation. This potential cost savings would be realized by utilizing on‐site evaluation despite the additional fee due to a higher rate of specimen adequacy. Based on this study, on‐site cytopathologic evaluation of FNA specimens is accurate, cost‐effective, and has improved patient care at our institution. Diagn. Cytopathol. 2002;27:1–4. © 2002 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dc.10065

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 367

Metadata

Authors
Nasuti, J. F., Gupta, P. K., & Baloch, Z. W.
Venue
Diagnostic Cytopathology
Publisher
Wiley
Published
2002-06-27
Volume
27
Issue
1
Pages
1-4
ISSN
  • 1097-0339 (ISSN-L)
  • 8755-1039
OpenAlex
W2168820510
Cited by
367
References
20
FWCI
2.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnostic value and cost‐effectiveness of on‐site evaluation of fine‐needle aspiration specimens: Review of 5,688 cases. https://app.cochat.ai/papers/10.1002/dc.10065
The paper
Nasuti, J. F., Gupta, P. K., & Baloch, Z. W. (2002). Diagnostic value and cost‐effectiveness of on‐site evaluation of fine‐needle aspiration specimens: Review of 5,688 cases. Diagnostic Cytopathology. https://doi.org/10.1002/dc.10065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.